Table 2.
Persistence rates for biologic compounds at 12 months
| Persistence | Total (n = 348) | ADA (n = 105) | CER (n = 29) | ETA (n = 100) | GOL (n = 20) | INF (n = 9) | SEC (n = 53) | UST (n = 32) |
|---|---|---|---|---|---|---|---|---|
| Persistence, mean no. of days (SD) | 289 (103) | 285 (107)* | 273 (120)* | 276 (110)** | 309 (82) | 305 (92) | 291 (92)* | 334 (72) |
| Did not persist, n (%) | 148 (42.5) | 44 (41.9) | 14 (48.3) | 49 (49.0) | 8 (40.0) | < 5 (–) | 24 (45.3) | 6 (18.8) |
| Discontinued, n (%) | 93 (26.7) | 22 (21.0) | 7 (24.1) | 30 (30.0) | 5 (25.0) | < 5 (–) | 22 (41.5) | 5 (15.6) |
| Switched, n (%) | 55 (15.8) | 22 (21.0) | 7 (24.1) | 19 (19.0) | < 5 (–) | < 5 (–) | < 5 (–) | < 5 (–) |
| bDMARD after first switch, n (%) | ||||||||
| ABA | < 5 (–) | 0 | < 5 (–) | 0 | 0 | 0 | 0 | 0 |
| ADA | 10 (2.9) | 0 | < 5 (–) | 5 (5.0) | < 5 (–) | 0 | 0 | < 5 (–) |
| CER | 10 (2.9) | < 5 (–) | 0 | < 5 (–) | 0 | < 5 (–) | < 5 (–) | 0 |
| ETA | 8 (2.3) | 7 (6.7) | < 5 (–) | 0 | 0 | 0 | 0 | 0 |
| GOL | < 5 (–) | < 5 (–) | 0 | 0 | 0 | 0 | 0 | 0 |
| INF | < 5 (–) | < 5 (–) | 0 | < 5 (–) | 0 | 0 | 0 | 0 |
| IXE | < 5 (–) | 0 | 0 | < 5 (–) | < 5 (–) | 0 | < 5 (–) | 0 |
| SEC | 11 (3.2) | < 5 (–) | < 5 (–) | 6 (6.0) | 0 | 0 | 0 | 0 |
| UST | 7 (2.0) | < 5 (–) | < 5 (–) | < 5 (–) | < 5 (–) | 0 | 0 | 0 |
| Persisted, n (%) | 200 (57.5) | 61 (58.1) | 15 (51.7) | 51 (51.0) | 12 (60.0) | 6 (66.7) | 29 (54.7) | 26 (81.3) |
Patient counts below 5 are reported as < 5 due to data protection regulations
ABA abatacept, ADA adalimumab, CER certolizumab pegol, ETA etanercept, GOL golimumab, INF infliximab, IXE ixekizumab, SD standard deviation, SEC secukinumab, UST ustekinumab
*P < 0.05 and **P < 0.01 compared with ustekinumab using the log-rank test